Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Large Decrease in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCPGet Rating) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 139,900 shares, a decline of 23.8% from the April 15th total of 183,600 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average daily volume of 268,600 shares, the days-to-cover ratio is currently 0.5 days.

Several brokerages recently issued reports on COCP. HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Cocrystal Pharma in a research report on Monday, March 14th. Noble Financial restated a “buy” rating and issued a $5.00 price objective on shares of Cocrystal Pharma in a research report on Thursday.

Shares of COCP traded up $0.03 on Monday, reaching $0.41. 5,115 shares of the company’s stock were exchanged, compared to its average volume of 378,590. The business has a 50 day moving average price of $0.51 and a two-hundred day moving average price of $0.62. Cocrystal Pharma has a 12 month low of $0.37 and a 12 month high of $1.49.

Cocrystal Pharma (NASDAQ:COCPGet Rating) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). As a group, analysts expect that Cocrystal Pharma will post -0.16 EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the business. Mariner LLC raised its position in shares of Cocrystal Pharma by 50.0% in the 3rd quarter. Mariner LLC now owns 300,055 shares of the company’s stock valued at $315,000 after acquiring an additional 100,000 shares during the period. Barclays PLC boosted its position in shares of Cocrystal Pharma by 248.5% during the third quarter. Barclays PLC now owns 26,665 shares of the company’s stock worth $28,000 after purchasing an additional 19,014 shares in the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in shares of Cocrystal Pharma by 108.7% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 24,243 shares of the company’s stock valued at $25,000 after buying an additional 12,625 shares during the period. Geode Capital Management LLC increased its position in shares of Cocrystal Pharma by 43.4% in the 3rd quarter. Geode Capital Management LLC now owns 800,602 shares of the company’s stock valued at $840,000 after buying an additional 242,270 shares in the last quarter. Finally, LPL Financial LLC raised its stake in Cocrystal Pharma by 16.3% during the 3rd quarter. LPL Financial LLC now owns 178,500 shares of the company’s stock worth $187,000 after buying an additional 25,000 shares during the period. Hedge funds and other institutional investors own 15.43% of the company’s stock.

About Cocrystal Pharma (Get Rating)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

See Also

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.